CD160 and bladder transitional cell carcinoma: Further research into the expression and spatial analysis of KLRK1, NCR2, CD2, and CD160 and the cells that express them using multiplex immunohistochemistry may reveal the importance of these receptor-ligand interactions for anti-tumour immunity in the BLCA TME and their association with improved prognosis of BLCA patients.